Skip to main content

BioCryst Pharmaceuticals, Inc. (BCRX)

NASDAQ: BCRX · Delayed Price · USD
15.37 -0.02 (-0.13%)
Sep 23, 2021 4:00 PM EDT - Market closed
Market Cap2.73B
Revenue (ttm)79.14M
Net Income (ttm)-214.09M
Shares Out178.13M
EPS (ttm)-1.21
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,854,651
Open15.40
Previous Close15.39
Day's Range15.18 - 15.46
52-Week Range3.30 - 18.48
Beta2.58
AnalystsBuy
Price Target21.27 (+38.4%)
Est. Earnings DateNov 4, 2021

About BCRX

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial ...

IndustryBiotechnology
IPO DateMar 3, 1994
CEOJon Stonehouse
Employees246
Stock ExchangeNASDAQ
Ticker SymbolBCRX
Full Company Profile

Financial Performance

In 2020, BCRX's revenue was $17.81 million, a decrease of -63.53% compared to the previous year's $48.84 million. Losses were -$182.81 million, 67.9% more than in 2019.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for BCRX stock is "Buy." The 12-month stock price forecast is 21.27, which is an increase of 38.39% from the latest price.

Price Target
$21.27
(38.39% upside)
Analyst Consensus: Buy

News

BioCryst to Present at 2021 Cantor Virtual Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 2021 Cantor Virtual Healthcare Conferen...

2 days ago - GlobeNewsWire

NICE Recommends BioCryst's Hereditary Angioedema Med

The U.K.'s National Institute for Health and Care Excellence (NICE) has recommended BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) Orladeyo (berotralstat) for hereditary angioedema (HAE). The recommendat...

1 week ago - Benzinga

NICE Recommends BioCryst's ORLADEYO® (berotralstat), the First Oral, Once-daily Therapy, to Prevent Attacks in HAE Pa...

RESEARCH TRIANGLE PARK, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the United Kingdom's (UK) National Institute for Health and Care Excel...

1 week ago - GlobeNewsWire

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 2021 Virtual Wells Fargo Healthcare Con...

2 weeks ago - GlobeNewsWire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 18...

3 weeks ago - GlobeNewsWire

US Government Exercises Option To Buy Additional Doses Of BioCryst's Flu Med

The U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) Rapivab (peramivir injection) The ...

3 weeks ago - Benzinga

U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Delivery to ...

RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised i...

3 weeks ago - GlobeNewsWire

BioCryst Appoints Dr. Steven Galson to Board of Directors

RESEARCH TRIANGLE PARK, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed former director of the U.S. Food and Drug Admi...

4 weeks ago - GlobeNewsWire

BioCryst Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Canada and Swissmedic

RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the new drug submission for ORLADEYO® (berotralstat) has been accepted ...

4 weeks ago - GlobeNewsWire

2 Soaring Biotech Stocks With More Fuel in the Tank

These recent winners still have a long way to run.

Other symbols:FULC
1 month ago - The Motley Fool

BioCryst Stock Jumps After Pulling Out $200M Equity Raise

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has withdrawn its proposed public offering of $200 million of its stock and pre-funded warrants. The Company says that it is well-capitalized, with cash, cash...

1 month ago - Benzinga

BioCryst Withdraws Public Offering

RESEARCH TRIANGLE PARK, N.C., Aug. 10, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that it has withdrawn its proposed public offering. With our strong balance ...

1 month ago - GlobeNewsWire

BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants

RESEARCH TRIANGLE PARK, N.C., Aug. 09, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that it is offering to sell $200 million of its common stock and, in lieu of...

1 month ago - GlobeNewsWire

Why BioCryst Pharmaceuticals Rose 8% on Thursday

The company's first commercial drug launch keeps exceeding expectations.

1 month ago - The Motley Fool

BioCryst Pharma Stock Heads Higher Thursday: Here's Why

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares were trading higher Thursday after the company reported second-quarter financial results. The company reported revenue of $50 million, with $28.5 mill...

1 month ago - Benzinga

Tuesday Afternoon Analyst Upgrades and Downgrades: Exxon Mobil, First Solar, Tesla and More

With the trading day more than halfway over, the broad markets were pushing higher yet again.

1 month ago - 24/7 Wall Street

3 Biotech Stocks That Could Rocket Higher

Over the past year, these small-cap drugmakers have done well by their shareholders, and more big catalysts could be coming.

Other symbols:LLYRIGL
1 month ago - The Motley Fool

BioCryst to Report Second Quarter 2021 Financial Results on August 5

RESEARCH TRIANGLE PARK, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2021 financial results on Th...

2 months ago - GlobeNewsWire

BioCryst Outlines Pivotal Trial Designs For BCX9930 In Rare Blood Disorder

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has announced the designs for REDEEM-1 and REDEEM-2, two upcoming pivotal trials for its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturn...

2 months ago - Benzinga

BioCryst Announces Designs for REDEEM-1 and REDEEM-2 Pivotal Trials with BCX9930 as Oral Monotherapy for Patients wit...

RESEARCH TRIANGLE PARK, N.C., July 15, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the designs for REDEEM-1 and REDEEM-2, two upcoming pivotal trials with its ...

2 months ago - GlobeNewsWire

BioCryst Shares 96-Week Orladeyo Data Highlighting 80% Reduction In HAE Attacks

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has announced 96-week data from the Phase 3 APeX-2 trial for Orladeyo (berotralstat), showing a sustained reduction in hereditary angioedema (HAE) attacks pat...

2 months ago - Benzinga

BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by 80 Percent from ...

—Multiple data presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2021 highlight durability of effect and long-term safety of ORLADEYO— —Multiple data prese...

2 months ago - GlobeNewsWire

ORLADEYO™ (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid C...

RESEARCH TRIANGLE PARK, N.C., July 01, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced multiple upcoming data presentations at the European Academy of Allergy and ...

2 months ago - GlobeNewsWire

Up 126% in 2021, Could BioCryst Pharmaceuticals Go Even Higher?

There's more than one opportunity for it to do so.

2 months ago - The Motley Fool

BioCryst Announces Acceptance and Accelerated Review of the ORLADEYO™ (berotralstat) Marketing Application by the Isr...

— Neopharm Ltd. selected as exclusive distribution and supply partner of ORLADEYO in Israel — — Neopharm Ltd. selected as exclusive distribution and supply partner of ORLADEYO in Israel —

3 months ago - GlobeNewsWire